PE20191407A1 - Uso de gaboxadol en el tratamiento de tinnitus - Google Patents

Uso de gaboxadol en el tratamiento de tinnitus

Info

Publication number
PE20191407A1
PE20191407A1 PE2019001533A PE2019001533A PE20191407A1 PE 20191407 A1 PE20191407 A1 PE 20191407A1 PE 2019001533 A PE2019001533 A PE 2019001533A PE 2019001533 A PE2019001533 A PE 2019001533A PE 20191407 A1 PE20191407 A1 PE 20191407A1
Authority
PE
Peru
Prior art keywords
gaboxadol
tinnitus
treatment
meniere
ameliorate
Prior art date
Application number
PE2019001533A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of PE20191407A1 publication Critical patent/PE20191407A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan metodos para tratar el tinnitus con gaboxadol o una sal farmaceuticamente aceptable del mismo. Tambien se proporcionan composiciones terapeuticas que pueden usarse para mejorar uno o mas sintomas del tinnitus. Se proporcionan metodos para tratar la perdida auditiva neurosensorial aguda o enfermedad de Meniere con gaboxadol o una sal farmaceuticamente aceptable del mismo. Tambien se proporcionan composiciones terapeuticas que se pueden usar para mejorar uno o mas sintomas de la perdida auditiva neurosensorial aguda o enfermedad de Meniere.
PE2019001533A 2017-02-03 2018-02-02 Uso de gaboxadol en el tratamiento de tinnitus PE20191407A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762454280P 2017-02-03 2017-02-03
US201762530528P 2017-07-10 2017-07-10
US201762536669P 2017-07-25 2017-07-25
PCT/US2018/016602 WO2018144827A1 (en) 2017-02-03 2018-02-02 Use of gaboxadol in the treatment of tinnitus

Publications (1)

Publication Number Publication Date
PE20191407A1 true PE20191407A1 (es) 2019-10-04

Family

ID=63038963

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001533A PE20191407A1 (es) 2017-02-03 2018-02-02 Uso de gaboxadol en el tratamiento de tinnitus

Country Status (17)

Country Link
US (3) US10071083B2 (es)
EP (1) EP3576738B1 (es)
JP (2) JP2020505432A (es)
KR (1) KR20190112046A (es)
CN (1) CN110402140A (es)
AU (1) AU2018215363A1 (es)
BR (1) BR112019015832A2 (es)
CA (1) CA3051586A1 (es)
DK (1) DK3576738T3 (es)
ES (1) ES2930899T3 (es)
HU (1) HUE060609T2 (es)
IL (1) IL268210A (es)
MX (1) MX2019009190A (es)
PE (1) PE20191407A1 (es)
PL (1) PL3576738T3 (es)
PT (1) PT3576738T (es)
WO (1) WO2018144827A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
AU2019405489A1 (en) 2018-12-17 2021-06-10 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
IL293924A (en) 2019-12-18 2022-08-01 Ovid Therapeutics Inc Goxadol for medical treatment in 1p36 deletion syndrome
KR20230028244A (ko) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
BRPI0509210A (pt) 2004-04-02 2007-08-28 Lundbeck & Co As H uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
LT2083811T (lt) 2006-11-22 2017-01-25 Clinical Research Associates, Llc Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
EP3108876A1 (en) 2011-10-13 2016-12-28 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
EP4335505A2 (en) 2012-11-30 2024-03-13 The Regents of The University of California Anticonvulsant activity of steroids
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
RS62006B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX2018001720A (es) 2015-08-11 2018-09-06 Ovid Therapeutics Inc Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US11123332B2 (en) * 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression

Also Published As

Publication number Publication date
KR20190112046A (ko) 2019-10-02
WO2018144827A1 (en) 2018-08-09
AU2018215363A1 (en) 2019-08-15
EP3576738A1 (en) 2019-12-11
ES2930899T3 (es) 2022-12-22
US20180344709A1 (en) 2018-12-06
US10071083B2 (en) 2018-09-11
BR112019015832A2 (pt) 2020-03-31
PL3576738T3 (pl) 2023-02-06
HUE060609T2 (hu) 2023-04-28
PT3576738T (pt) 2022-11-30
CN110402140A (zh) 2019-11-01
US10188635B2 (en) 2019-01-29
EP3576738B1 (en) 2022-10-12
JP2020505432A (ja) 2020-02-20
DK3576738T3 (da) 2022-11-28
US20180221355A1 (en) 2018-08-09
MX2019009190A (es) 2019-09-26
IL268210A (en) 2019-09-26
US20190111033A1 (en) 2019-04-18
JP2023011630A (ja) 2023-01-24
EP3576738A4 (en) 2021-02-17
CA3051586A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2017000050A1 (es) Terapia de combinación para el cáncer
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas